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The synthesis of a new PEG-solubilized gadolinium texaphyrin (Gd-Tex) conjugate containing a
malonate-Pt(NH3)2 moiety is described. The effect of the tumor localizing Gd-Tex macrocycle on
platinum activity was evaluated in cell culture. The malonate moiety, analogous to that present in
carboplatin, is expected to release an aquated Pt(NH3)2 species under physiological conditions. The
half-life in phosphate-buffered saline was found to be ca. 3 days at room temperature, and the
hydrolytic product released from the conjugate was collected and confirmed as Pt-based by flameless
atomic absorption spectrophotometry. Anti-proliferative activity was tested using A549 human lung
cancer and A2780 human ovarian cancer cell lines. In both cell lines, the activity of the Gd-Tex
conjugate was found to be similar to that of carboplatin. Efficacy against a Pt-resistant ovarian cell line
greater than that displayed by carboplatin was also observed.
Introduction
Cisplatin, carboplatin, and oxaliplatin (Fig. 1) are widely used
anti-cancer therapeutic agents. However, these agents also give
rise to systemic toxicity as the result, at least in part, of a
lack of tumor-specific tissue distribution. Many strategies have
been used to increase the tumor specificity of platinum drugs,
Fig. 1 Structures of cisplatin, carboplatin, oxaliplatin, motexafin gadolin-
ium, MGd 1, Gd-Tex-amine-Pt conjugate 2, Gd-Tex-aminosuccinate-Pt
conjugate 3.
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including conjugation to potentially site-directing molecules, such
as folate, poly(ethyleneglycol) (PEG), porphyrins, and peptides
among others.1-5 This work, which has been carried out within the
context of a general effort to improve the performance of platinum
drugs (by, e.g., delivering active forms of Pt specifically to tumor
cells and overcoming identified resistance mechanisms), to our
knowledge, has yet to produce an FDA-approved conjugate.
In previous work, we have described the synthesis of platinum
conjugates based on the structure of motexafin gadolinium
(MGd, 1).6-9 These were designed to exploit the tumor-localizing
properties of this well-studied expanded porphyrin derivative. Un-
fortunately, the resulting conjugates, which rely on either diamino
(2) or aminosuccinate (3) groups to affect Pt coordination, could
not be studied extensively in vitro due to a combination of poor
solubility and inherent instability (Fig. 1).7
The texaphyrins are members of the “expanded porphyrin”
class of macrocycles. These pentaaza analogues of porphyrins
allow for the coordination of larger metal cations and have
led to the development of several well-tolerated experimental
therapeutic agents.6 One of these, motexafin gadolinium, has been
the subject of several clinical trials, in which tumor localization
was demonstrated by MRI.10-14
The inorganic complex cisplatin, and its two FDA-approved
analogues, carboplatin and oxaliplatin, are DNA-modifying
agents that form interstrand and intrastrand crosslinks thus acting
as inhibitors of both bacterial and tumor growth.15-17 Extensive
study has elaborated mechanisms of action, profiles, specificity, ap-
plications, and patterns of resistance for these three drugs.15,16,18-20
As a general rule, therapeutic activity can be correlated with
hydrolytic loss of the non-nitrogen ligands (chloride or carboxyl),
giving rise initially to a mono-aquated species, which upon
completion of hydrolysis, generates the reactive DNA-binding
“diaquo” species.21-26 This rate of hydrolysis, which has been
extensively studied, is affected by pH, chloride ion concentration
in the case of cisplatin, and the presence or absence of other
nucleophiles.27-30




















































A number of conjugates involving platinum have been prepared
in an effort to enhance the therapeutic utility of cisplatin and
its analogues. Some archetypal Pt(II) conjugates are represented
by non-labile diamino systems, such as 2, amidosuccinate (as-
partate) complexes, represented by 3, and amino/amidomalonate
derivatives, such as 431 and 5 (Fig. 2). In the case of conjugate
2, attachment was affected via piperazine, whereas in the case of
conjugate 3, an aminosuccinato-platinum bonding interaction was
employed. While synthetically accessible, these systems demon-
strated poor solubility and low activity when subject to in vitro bio-
logical testing.7 In the case of the aminosuccinate species 4, its poor
performance was also ascribed to possible premature Pt release.
High lability also plagues platinum aminomalonate conjugates
in that they are reported to rearrange, giving amine-bound (Pt-N)
platinum species. Separately, these compounds demonstrated poor
anticancer activity.31-34 Amidomalonate conjugates, such as 5,
were susceptible to rapid hydrolysis (t1/2 = 1 hour) thus limiting
therapeutic utility.35
Fig. 2 Malonate-type Pt conjugates: aminomalonate 4, PEG-amidoma-
lonate 5, and folate-PEG 6. AA—amino acid.
Tissue-targeted conjugates have been recently developed. Ex-
amples include Pt(II)-PEG conjugates containing both an amino
acid linker (AA) and a nuclear localizing sequence (NLS),36 folate
containing complex 6,1 in addition to other conjugates containing
alkanes, long-chain PEG, steroids, and DNA intercalators.37,38
Within conjugate 6, the active species are separated by a PEG
linkage in addition to a propyl spacer separating the malonate
moeity and the nearby amide. This conjugate displayed increased
hydrolytic stability relative to 5 in addition to increased Pt uptake
in vitro cell studies in the M109 HiFR cells as determined through
a Pt assay.36 Efficacy evaluation of carboplatin and PEG solubi-
lized conjugate 6 gave IC50 values of 18.5 and 16.1 mM, respectively,
as inferred from methylene blue proliferation assays. A common
factor of these and other active compounds, such as oxaliplatin and
the “Platinum Blues”39 is Pt-dicarboxylate coordination. We thus
considered that the incorporation of such a Pt-complexing feature
would be advantageous in the construction of improved platinum-
gadolinium texaphyrin (Gd-Tex) conjugates. In this report, we
detail the synthesis of a new gadolinium texaphyrinmalonate-
Pt conjugate, complex 7 (Scheme 1), and show that its anti-
proliferative activity in vitro is comparable to that of carboplatin,
as determined from cell proliferation assays involving the A549
human lung cancer and A2780 human ovarian cell lines. We also
demonstrate that this conjugate displays higher in vitro activity
than carboplatin in the Pt-resistant 2780CP ovarian cell line.
Experimental
General procedures
Anhydrous solvents and starting materials were purchased by
Fisher Scientific and used without further purification un-
less otherwise specified. Solvents were dried over molecular
sieves, and dichloromethane (DCM) was dried over CaH2.
Intermediate 2,5-bis[(5-formyl-3-hydroxypropyl-4-methylpyrrol-
2-yl)methyl]-3,4-diethylpyrrole 13 was supplied by Pharmacyclics,
Inc.40 The starting Gd(OAc)3·4H2O and (NH3)2PtI2 were obtained
from Strem Chemical Co. and Johnson Matthey Biomedical
Materials, respectively.
Column chromatography was performed with Merck type 60
(230-400 mesh) silica gel using 9:1 DCM:MeOH containing
either HOAc or NH3 to deactivate the silica gel unless otherwise
indicated. Sep-Pak cartridges were purchased from Waters or
Fisher in 0.5-20 gram sizes of C-18, alumina, or silica gel. Thin
layer chromatography (TLC) was performed using Whatman K6F
aluminium backed silica gel plates, plastic backed alumina plates,
or glass backed C-18 plates. Silica gel TLC of organic soluble
samples commonly used EtOAc/hexanes or DCM as the eluents.
The conjugates, both before and after treatment with Pt(II), were
generally purified on RP-tC18 SPE (Waters Sep-Pak) columns.
HPLC analyses were performed on a Beckman System Gold or
Shimadzu Analytical/Preparative HPLC system equipped with
PDA detector and a Zorbax XDB 5 mM 5 ¥ 100 mm column.
An ammonium acetate buffer (30 mM, pH = 4.3)/acetonitrile
(MeCN) gradient (30-99% MeCN over 20 minutes) was used for
the analysis of the initial Gd-Tex product. A 0.1% TFA/MeCN
gradient (10-99% over 15 minutes unless otherwise noted) was
used for analysis of other intermediates. The MGd-Pt conjugate 7
was subject to HPLC analysis on a C-18 column using 0.1% TFA
and MeCN as the eluent and detection at 472 nm.
To study the nature of the product hydrolyzed from conjugate
7, 1.2 mg of 7 was dissolved in 6 mL of PBS and incubated
at room temperature for 4 days. At intervals of 24 h, 200 mL
aliquots were taken and placed on an RP-tC18 SPE (Waters Sep-
Pak) column. The column was then eluted with 4 mL of PBS
and the texaphyrin-free eluent collected in 4 ¥ 1mL fractions.
The fractions were analyzed for Pt content by flameless atomic
absorption spectrophotometry (FAAS), as previously described.41
Under the conditions used, the standard curve using a certified
1 mg Pt/ml stock solution (Sigma) was linear up to 2 mg/ml, with
an r2 of 0.998.
All 1H, and 13C NMR spectra were measured using a Varian
Mercury 400 (400 MHz) or a Varian Inova 500 (500 MHz)
spectrometer using CDCl3, D2O, CD3OD or dimethylformamide-
d7 (DMF-d7) as the solvents. The NMR chemical shifts are
reported in ppm relative to the solvent. Low resolution and
high resolution electrospray mass spectrometry (ESI MS) were
performed using a Thermo Finnigan LTQ instrument and a Qq-
FTICR (7 Tesla) instrument, respectively. Mass spectrometry
(LRMS, HRMS) was carried out by the University of Texas
at Austin Mass Spectrometry Facility. Elemental analyses were




















































Scheme 1 Synthesis of Gd-Tex-propylmalonate-Pt conjugate 7.
performed by Midwest Microlabs Inc. Electronic spectra were
recorded on a Beckman DU-7 spectrometer.
Synthesis
2-[2-(2-{2-[2-(2-Methoxy-ethoxy)-ethoxy]-ethoxy}-4,5-dinitro-
phenoxy)-acetylamino]-malonic acid di-t-butyl ester 10. To a
solution of 5.6 g (14 mmol) of acid 87 in 200 mL of DCM
containing 1.65 g (14 mmol) of N-hydroxysuccinimide (NHS) was
added 3.6 g (17 mmol) of dicyclohexylcarbodiimide (DCC). The
resulting solution was then stirred briefly. To the solution, 3.7 g
(14 mmol) of amine 91 was added. The solution was allowed to
stir overnight, filtered, and the solvent was evaporated off. The
crude residue was purified by flash chromatography over silica
gel (EtOAc:hexanes 1:1, eluent) followed by co-evaporation with
CHCl3 to provide 3.2 g (4.9 mmol, 35%) of 10 as an oil. HPLC
(monitoring at 329 nm): Tr 14.87 min, 91.24%. TLC (9:1 DCM:
MeOH): Rf = 0.2. MS (EI) [M+H]+ = 660. HRMS(EI) calculated
for C29H46N3O14 660.2980, found 660.2978. 1H NMR (400 MHz,
CDCl3) d 1.45 (s, 18 H), 1.60 (m, 2H), 1.81 (m, 2 H), 3.13 (t, J =
7.2 Hz, 1 H), 3.36 (m, 5 H), 3.53 (m, 2 H), 3.53 (m, 2 H), 3.61-3.67
(m, 4 H), 3.72 (m, 2 H), 3.93 (m, 2 H), 4.37 (m, 2 H), 4.62 (s, 2 H),
7.00 (br t, 1 H), 7.52 (s, 1 H), 7.52 (s, 1 H). 13C NMR (100 MHz,
CDCl3) d 25.6, 26.9, 2707, 38.6, 53.2, 58.8, 68.8, 69.2, 69.7, 70.3,
70.4, 70.7, 81.4, 109.2, 110.2, 136.0, 137.8, 149.4, 151.9, 166.2,
168.5.
2-(3-(2-(2-(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)-4,5-dinitro-
phenoxy) ethanamido)propyl)propanedioic acid, 11. To 1.7 g
(2.6 mmol) of di-t-butyl malonate 10 was added 15 mL of 90%
v/v TFA in H2O. The resulting solution was stirred for 1 h and
was monitored by TLC and 1H NMR spectroscopic analysis. Once
starting material 10 was no longer visible by these techniques, the
solvent was removed under reduced pressure. The resulting pellet
was triturated with 50 mL CHCl3 and evaporated to dryness under
reduced pressure. The product was carried forward without further
purification.




14,16,18,20,22(25),23-tridecaene 14. The di-acid 11 obtained as
above was dissolved in 50 mL of MeOH containing 0.42 g
of 10% Pd-C. The resulting suspension was subjected to high-
pressure hydrogenation (40 psi) for 18 h. The suspension was then
passed through Celite. The filtrate was then added to a solution
consisting of 50 mL of MeOH, 0.5 mL of 3 N aq. HCl, and
1.3 g (2.7 mmol) of tripyrrane 13.40 The solution was then stirred
for 3 h in a 50 ◦C oil bath, and monitored by TLC. Once the
reaction was deemed complete by TLC analysis, the solvent was
evaporated under reduced pressure. To the resulting residue was
added 100 mL MeOH, 4 mL of Et3N, and 1.1 g (2.7 mmol, 1.05




















































equiv.) of Gd(OAc)3·4H2O. The solution was then stirred to the
open atmosphere for 2 h in a 50 ◦C oil bath. The reaction was then
deemed complete by TLC and 4 mL of HOAc was added dropwise.
Volatiles were removed under reduced pressure, and the resulting
residue was dissolved in 10 mL of 30 mM NH4OAc (pH 4.3) and
loaded on a 10 g C-18 SPE cartridge. Elution with 80:20 MeCN:
30 mM NH4OAc (pH 4.3) gave fractions rich in the product.
These fractions were diluted with NH4OAc (pH 4.3) and loaded
onto a new 10 g C-18 SPE cartridge. The column was washed
with water and product 14 eluted with MeOH. Evaporation of the
product-containing fractions and titration with Et2O gave 0.18 g
(0.16 mmol, 6.2%) of 14 as a green solid. HPLC (monitoring at 472
nm): Tr 4.28 min 96.24%. MS (EI) [M - 2 OAc]+ 1084. HRMS(EI)
calculated for C49H62GdN6O12 1084.3667, found 1084.4425. Anal.
Calcd for C51H65GdN6O14: C 53.57%; H 5.73%; N 7.35%. Found:
C 53.07%; H 5.73%; N 7.55%.





To a solution of 230 mg (0.201 mmol) of 14 in 10 mL of
MeOH was added 40 mL of 100 mM aq. NaNO3, and the
resulting suspension was added to a 10 g C-18 SPE cartridge.
The nitrated form of 14 was eluted with 15 mL of MeOH. To the
methanolic fractions was added 8.0 mL of a 50 mM solution of
aq. (NH3)2Pt(H2O)2(NO3)2.42 The resulting solution was stirred
in the dark for 48 h. The solution was diluted with an equal
volume of 40 mM aq. NaNO3and loaded on a 10 g C-18 SPE
cartridge. Elution with 60% v/v 40 mM aq. KNO3/MeOH
effected removal of various unidentified impurities. Conjugate
7 was then eluted from the column using with 40% v/v 40 mM
aq. KNO3/MeOH. The fractions containing conjugate 7 were
desalted by diluting 1:1 with 40 mM aq. KNO3, applying to a new
C-18 SPE cartridge, washing with 10 mM aq HNO3, and eluting
with MeOH containing 5% HNO3 (10 mM, aqueous). Addition of
Et2O precipitated product 7, which was collected by centrifugation
to give 84 mg (0.06 mmol, 30%) of 7 as a green solid.HPLC
(monitoring at 472 nm): Tr 7.36 min 95.97%. MS (EI) (M - NO3)+
1374. HRMS(EI) calculated for C49H66GdN9O15GdPt: 1373.3567;
found: 1373.3574. UV lmax (log e): 419 (sh), 474 1.19e5, 742
3.43e4. Anal. Calcd for C49H67GdN10O18GdPt: C 40.97%; H
4.70%; N 9.75%. Found: C 40.67%; H 4.81%; N 9.46%.
In vitro anti-proliferative activity
The proliferation of exponential phase cultures of A549, A2780
and 2780CP cells was assessed by tetrazolium salt reduction.43
In brief, tumor cells were seeded in 96-well microtiter plates
at 3000, 300 and 1000 cells/well, respectively, and allowed to
adhere overnight in RPMI 1640 medium supplemented with
2 mM L-glutamine, 10% heat inactivated fetal bovine serum,
and antibiotics (200 U/cm3 penicillin and 200 mg/cm3 strepto-
mycin). Stock solutions of carboplatin (5% aqueous mannitol
or ultrapure H2O), MGd (methanol), or conjugate 7 (methanol)
were formulated in the indicated solvent for maximum stability
and then diluted in medium for secondary stocks of 40-1000 mM
depending on the cell line being tested. Secondary stock solutions
were serially diluted in medium and immediately added to wells,
whereupon plates were incubated at 37 ◦C under a 5% CO2/95%
air atmosphere. After a total of 3 (A549 cells) or 5 (A2780 or
2780CP cells) days, the tetrazolium dye, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Chemical)
was added to each well and the plates incubated at 37 ◦C,
whereupon the medium was removed, the formazan dissolved and
absorbances measured at 560-650 nm using a microplate reader
(Molecular Devices, Sunnyvale, CA). Absorbances were corrected
for background and the values normalized to wells containing
untreated cells to allow plate-to-plate comparison. The data are
shown as mean inhibition of proliferation or growth as a % of
control cells from 8-10 replicate values. Error bars represent the
associated standard deviation.
Results and discussion
Synthesis of Gd-Tex platinum(II) conjugate
The apparent success of Pt conjugate 6 led us to attempt the
synthesis of texaphyrin-Pt(II) conjugate 7, bearing a carboplatin-
like coordination site. The synthesis of this new conjugate is
shown in Scheme 1. Amide bond formation between acid 87
and amine 91 was accomplished using dicyclohexylcarbodiimide
(DCC) in the presence of N-hydroxysuccinimide (NHS). The
resulting dinitrophenyl malonate diester 10 was then treated
with 9:1 TFA/H2O, employing conditions utilized in peptide
deprotection;44 this effected deprotection of the acid groups, giving
diacid 11. Although removal of the malonate t-butyl groups was
expected to be facile, we found that more traditional conditions,
such as treatment with neat TFA, formic acid, or TMS-triflate,
were not effective.45,46Dinitro 11 was then converted to diamine 12
by catalytic reduction. Cyclization between equimolar amounts of
diamine 12 and dialdehyde 13 followed by oxidative metallation
with Gd(OAc)3 provided Gd coordinated texaphyrin 14 as the
dominant product (6.2% yield based on 10). Analysis of the
crude mixture indicated less than 20% formation of the mono-
decarboxylation biproduct. These two products were separated
by solid phase extraction (SPE) on C-18 using acetonitrile and
ammonium acetate buffer. The resulting purified texaphyrin,
a paramagnetic complex, was then characterized by elemental
analysis, HPLC, and mass spectrometry.
With the Gd-Tex-derived malonate complex 14 in hand, efforts
were made to affect platination of the malonic acid moiety. Initial
attempts using (NH3)2Pt(H2O)2·(NO3)2 (hereafter Pt-diaquo) as
a platinum(II) source proved unsuccessful. Literature reports30
detailing the reaction of Pt-diaquo species with acetate, led us
to consider that the acetate counter anion present in 14 might
be interfering with this complexation process. Complex 14 was
thus subject to nitrate-for-acetate ion exchange by loading 14
on a C-18 Sep-Pak column and eluting with NaNO3 buffer
to remove the NH4OAc buffer used in the initial purification.
Removal of ammonia (presumably in its protonated form) and
acetate, provided the nitrated species suitable for coordination to
platinum.30
A methanol solution of the resulting texaphyrin (nitrate)
complex analogous to 14 was mixed with an aqueous solution
containing one equivalent of diaquo Pt complex and left to stir
for 24 hours. Quenching the reaction by pouring into water
gave a green solid in 30% yield (based on 14). Analysis by UV




















































spectroscopy, LCMS, and elemental analysis provided support for
this species being the desired platinated-texaphyrin conjugate 7. As
determined via HPLC studies, platinated Gd-Tex-based 7 eluted
faster than the starting texaphyrin-diacid 14. Final purification
was thus affected on a reverse phase C-18 column using a
methanol/KNO3 mobile phase. Desalting was also effected on
a reverse phase C-18 column by washing the bound material with
water prior to elution with methanol. This produced product
7, a paramagnetic species, which was characterized by HPLC,
mass spectrometry, and elemental analysis.It was this material
that was tested in the cell proliferation studies (vide infra).
Due to the distance between the paramagnetic Gd texaphyrin
center and the Pt center, it was thought that characterization
of the Pt coordination environment and the organic framework
of the proposed chelates might be possible using 1H, 13C, and
195PtNMR. These studies were attempted; however, presumably as
a consequence of the paramagnetism of the Gd center, the peaks
obtained were either too broad for characterization or simply not
visible. However, the structure given for 7 is consistent with all
other available evidence. Moreover, an alternative formulation,
involving N-Pt-O coordination rather than O-Pt-O ligation, was
ruled out on the basis of the larger chelate ring that would need to
be formed and the slower hydrolysis rate expected for an N-Pt, as
compared to O-Pt linkage.
As anticipated given the O-Pt-O coordination environment
present in conjugate 7, aqueous solutions of this complex were
found to hydrolyze to produce Pt(NH3)2 species and organic
fragments over time, as inferred from HPLC and FAAS analysis.
Initial HPLC analysis of aqueous solutions of the platinated-Gd-
Tex complex 7 revealed decreasing levels of the platinated material
and increasing levels of the Gd-Tex-diacid 14 as a function of time.
However, this proved to be a reversible process; the HPLC trace
corresponding to 7 could be regenerated by the addition of excess
Pt-diaquo (data not shown). Further, conjugate 7 proved to be
stable both in the presence of high concentrations of nitrate (0.5-
1.0 M, aq.) and in methanol solution.
Stability studies of Gd-Tex-Pt conjugate 7
Given the reversible loss of Pt seen during the purification of Gd-
Tex-Pt conjugate 7, efforts were made to quantify the rate of this
presumed hydrolytic process. Towards this end, stability studies
were carried out in two different media using HPLC (Fig. 3). These
studies revealed that the half-life of platinum loss for conjugate 7 in
phosphate-buffered saline is ca. 72 h, a value that is commensurate
with the rate of carboplatin hydrolysis.24
As expected, the conjugate proved much more stable in
methanol than in aqueous medium (Fig. 3a).
The hydrolysis of conjugate 7 was further monitored by FAAS
(Fig. 3b). Conjugate 7 was dissolved in PBS buffer and incubated
for 4 days. Aliquots were sampled immediately and at 24 h
intervals. They were processed using RP-tC18 SPE columns
with PBS as the eluent. The colored texaphyrin complex was
retained on the column, under conditions where the more polar
hydrolysed Pt species is eluted. The collected 1 mL fractions were
subjected to FAAS for determination of Pt concentration. The
Pt-containing hydrolysis product(s) formed from 7 was initially
negligible, but became measurable within 24 hours and continued
to form thereafter. Pt elution was almost complete using 4 mL
Fig. 3 (a) HPLC hydrolysis study of Gd-Tex-Pt conjugate 7 in methanol
(grey line) and phosphate buffered saline (PBS) (black line). Samples in
PBS display a t1/2 of ca. 3 days. (b) Pt concentration in eluates collected
from a Sep Pak column pre-loaded with an aliquot of conjugate 7 in PBS
incubated over 4 days. Each fraction represents 1 mL of eluent.
PBS for elution, as indicated by a low Pt concentration in the
fourth fraction at each time-point. Due to the lack of retention
on the column, the Pt is most likely inorganic in nature and may
consist of cisplatin due to the high chloride concentration in the
PBS buffer.
Antiproliferative activity of Gd-Tex-Pt conjugate 7
Initial tests for antiproliferative activity were carried out using
the A549 human lung cancer cell line. These studies revealed
that conjugate 7 had a low level of efficacy, but one that was
similar to carboplatin or an equimolar combination of MGd
and carboplatin (Fig. 4). MGd alone had no effect on A549
cell proliferation. This finding, coupled with the duration of the
treatment (3 days) and the measured half-life of Pt release from 7
(about 3 days, Fig. 3), is consistent with the notion that conjugate
7 undergoes hydrolysis in tissue culture medium at a rate similar
to that of carboplatin. It also led us to consider whether conjugate
7 could better be evaluated in more sensitive cell lines where both
Pt-based activity and resistance had previously been observed.47
With such considerations in mind, tests were carried out using
the A2780 human ovarian cancer cell line and an ostensibly
isogenic cisplatin-resistant cell line (2780CP) (Fig. 5). As before,
the effect of conjugate 7 on cell proliferation was compared to that




















































Fig. 4 Effect of conjugate 7 on cell proliferation. A549 lung cancer
cells were incubated with inhibitors for 3 days at 37 ◦C in 5% CO2
and relative proliferation measured by tetrazolium salt reduction. The
anti-proliferative activity of MGd, carboplatin, or the combined treatment
is shown for comparison. Error bars represent standard deviation.
Fig. 5 MTT Cell proliferation assay with A2780 (a) and cisplatin
resistant 2780CP (b) ovarian cancer cell lines in the presence of variable
concentrations of indicated drug. The drug was added to cells and
incubated for 5 days at 37 ◦C in 5% CO2. Error bars represent standard
deviation.
of equimolar concentrations of carboplatin, MGd, or a mixture
of these two compounds. Carboplatin (IC50 = 1.6 mM) provided a
dose-responsive profile that was similar to literature values using
this cell line.47 Conjugate 7 displayed a similar level of activity
(IC50 = 1.4 mM) as carboplatin within error. This similarity in
activity is encouraging considering the many known platinum
conjugates with reduced activity.36,48 While it may be inferred from
the similarity in IC50 values between carboplatin and conjugate 7
that activity may be attributed to platinum delivery, this has yet
to be shown experimentally. An antiproliferative effect was also
observed using higher concentrations of MGd (IC50 = 6.3 mM).
However, no significant synergistic effects were observed with
cells incubated with equimolar amounts of carboplatin and MGd
(IC50 = 1.2 mM).
Cell proliferation studies were also performed with platinum
resistant ovarian cancer cells (2780CP). In this instance, cells
incubated in the presence of the texaphyrin complex, i.e., treatment
with MGd + carboplatin, MGd, or conjugate 7, were inhibited to
a similar degree, with IC50 values of 11.6, 13.7, and 14.4 mM,
respectively. The activity of carboplatin was lower (26.3 mM),
consistent with literature values.46 The texaphyrin containing treat-
ments provided for a roughly two fold greater effect as compared
to treatment with carboplatin alone. While this is an encouraging
result, it is important to note that at this time it remains unknown
whether the activity of conjugate 7 is attributable to the texaphyrin
complex, the active platinum species, or a combination of both.
Further studies with additional conjugates are thus planned in an
effort to determine the relative contributions of these and other
factors (e.g., cell uptake) that can influence cell proliferation.
Conclusions
In attempts to develop a system for the targeted delivery of
platinum to cancer cells, conjugate 7, containing a Gd-Tex and
malonate-Pt(NH3)2 moieties, was designed and synthesized. The
tumor localizing Gd-Tex core was intended to act as a delivery
vehicle for the coordinated platinum. The malonate chelating
group, analogous to that present in carboplatin, was designed
to release Pt under physiological conditions. The rate of release
in phosphate-buffered saline was found to be ca. 3 days at room
temperature. Anti-proliferative activity was tested initially using
the A549 human lung cancer cell line and then more extensively in
the A2780 human ovarian cancer cell line. In both cases the activity
was found to be similar to that of carboplatin. Activity against
a Pt-resistant ovarian cell line (2780CP) was greater than that
displayed by carboplatin. While the activity profiles of conjugate 7
are highly encouraging, it should be noted that the mechanism of
action of 7 is not yet known. Possible mechanisms include induced
oxidative stress via the texaphyrin core, DNA crosslinking via the
active platinum agent, a combination of both, or an entirely new
mechanism of action yet to be elucidated. Further studies with
additional conjugates are thus planned in an effort to understand
the activity of 7 and related texaphyrin-based platinum species.
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